Vancomycin-Variable Enterococcus faecium Prevalence and Patient Factors

47% of vanA-positive Enterococcus faecium sterile site isolates were vancomycin-variable. The study prospectively collected isolates from Toronto hospitals between January 2015 and June 2016, reviewing patient charts for 36 VRE, 25 VVE, and 79 VSE bacteremia cases. Clinical characteristics like Pitt bacteremia and Charlson scores were analyzed as mortality predictors.

Use Cases

• Analyze the association between Pitt bacteremia score and 30-day mortality across VVE, VRE, and VSE patient groups.
• Compare the prevalence of central venous catheter-associated bacteremia among VVE (44%), VRE (57%), and VSE (28%) patient cohorts.
• Investigate the clonality of strains from breakthrough bacteremia cases using pulsed-field gel electrophoresis (PFGE) data.
• Model mortality risk using independent predictors like Charlson comorbidity score and Pitt bacteremia score from patient chart reviews.

Strengths

• Prevalence of VVE among vanA-positive isolates is quantified at 47% (18/38).
• Clinical chart reviews cover a defined cohort of 140 total patients (36 VRE, 25 VVE, 79 VSE).
• Data collection spans a specific time range from January 2012 to June 2016 for bacteremia reviews.

Limitations

• Sample sizes for specific groups are relatively small (e.g., 25 VVE patients).
• Geographic scope is limited to hospitals within the Toronto Invasive Bacterial Diseases Network.
• The dataset's structure, column definitions, and raw data files are not described.

Provenance

Source

Dryad digital repository, authored by Philipp Kohler.

Collection Method

Prospective collection of sterile site isolates and retrospective chart reviews of bacteremia patients.

Time Range

Isolate collection: January 2015 to June 2016. Bacteremia review: January 2012 to June 2016.

Freshness

Data was last updated in June 2020.

Geography

Hospitals within the Toronto Invasive Bacterial Diseases Network, Canada.